Genedata Biopharma Open Forum @ Celgene

The deadline for registration is September 20, 2019.

Date
September 24, 2019 | 9:00–16:00

Location
Celgene Corporation
10300 Campus Point Dr.
San Diego, CA, USA

Directions
View on Google Maps

Join our unique one-day workshop to learn why the world's most innovative R&D-driven organizations are using the Genedata Biopharma Platform, the industry-leading workflow system for increasing efficiency and throughput in large-molecule discovery and development.

Genedata partners present case studies showing how they use the platform to improve their biologics R&D processes. Genedata product experts provide an update on the latest product developments and an outlook on upcoming new functionalities. Attend the Open Forum to network with your peers and:

  • Hear customer case studies on how to best set up, operate, and use the Genedata Biopharma Platform
  • Share valuable tips on new ways to streamline R&D workflows and transform business processes
  • Discuss how the Genedata Biopharma Platform helps to overcome critical issues and bottlenecks in biopharma R&D
  • Find out how others have deployed, implemented, and adopted the Genedata Biopharma Platform to make their biopharma R&D faster and better

Please use the form to register. Participation is free on a first-come, first-served basis.

Agenda

Time Schedule Speaker
09:00 Registration & Coffee
09:50 Welcome & Opening Remarks Hari Hariharan, Executive Director of Biotherapeutics, Celgene Corporation, San Diego, CA, USA
10:00 Genedata Biopharma Platform Introduction
An E2E Solution for Streamlining Large-molecule R&D Workflows
Andrew Lynch, Scientific Consultant, Genedata, Boston, MA, USA
10:30 Keynote Presentation
Genedata Biologics in the Data Biosphere: Keeping Our Heads in the Cloud
Jeffrey Johnson, Principal Scientist, Biotherapeutics & David Liu, Associate Director, R&D Cloud Solution Partner, Celgene Corporation, San Diego, CA, USA
11:15 Refreshment Break
11:30 Pfizer Case Study
From Spreadsheets Towards a Centralized End-to-End Bio Repository and Analysis Platform
Joel Bard, Associate Research Fellow, BioMedicine Design, Pfizer, Cambridge, MA, USA
12:00 Janssen Case Study
Traceability, Findability, and Usability
Ruo Steensma, IT Director, Business Technology Leader, Janssen Research and Development, La Jolla, CA, USA
12:30 Lunch
1:30 Celgene Case Study
Utilizing Genedata Biologics’ Versatility for Cloud Software Integrations
Shagun Doshi, Business Analyst, IT - Scientific Systems & Innovations, Celgene Corporation, San Diego, CA, USA
1:50 Celgene Case Study
Utilizing Genedata Biologics for Protein Binding Characterization
Jon Lloyd, Sr. Research Associate, Biotherapeutics, Celgene Corporation, San Diego, CA, USA
2:10 Celgene Case Study
From Chaos to Order ‒ Efficient Data Management with Genedata Biologics
Bhavya Vivek, Associate Scientist, Biotherapeutics, Celgene Corporation, San Diego, CA, USA
2:30 Refreshment Break
2:45 Live Demonstration
Key Workflows in Genedata Biologics® & Genedata Bioprocess®
Yang-Chieh Chou, Scientific Consultant, Genedata, San Francisco, CA, USA
3:15 Panel Discussion Facilitated by Christopher Smith, Head of Biologics US, Genedata, Boston, MA, USA
3:45 Closing Remarks Adrienne Craig-Kennard, Business Development Manager, Genedata, San Francisco, CA, USA
4:00 End of Open Forum

Speaker Biographies

Joel Bard, Associate Research Fellow, BioMedicine Design, Pfizer, Cambridge, MA, USA
Joel has a B.M. in oboe from the Cleveland Institute of Music, a M.M in orchestral conducting from the Juilliard School, and a Ph.D. in biochemistry from Harvard University.  He originally joined Genetics Institute in 2001 as an X-ray crystallographer and ended up at Pfizer through the acquisition of GI by Wyeth and the subsequent acquisition of Wyeth by Pfizer.  He works on the structural biology of antibody-antigen interactions and leads biotherapeutics discovery programs, but is currently spending most of his time co-leading, along with Yuan Lin from Business Technology, the implementation of Genedata Biologics in Pfizer.

Yang-Chieh Chou, Scientific Consultant, Genedata, San Francisco, CA, USA
Yang-Chieh works closely with major biopharmaceutical companies globally to help streamline R&D workflows and has expertise in next-gen protein design and immuno-oncology, with a focus on engineering design workflows, such as bi/multi-specifics and CAR-T formats. In addition to deployment and training, he is responsible for projects ranging from process automation and system integration to data migration. Prior to joining Genedata, Yang-Chieh earned his PhD in structural biology from the University of Toronto and a MSc in immunology from the National Yang Ming University. He is experienced at antibody structure and informatics databases and holds patents in antibody engineering, bispecifics design, and antibody characterization method development.

Shagun Doshi, Business Analyst, IT - Scientific Systems & Innovations, Celgene Corporation, San Diego, CA, USA
Shagun has a B.S in Biology from Santa Clara University. She began at Celgene as an intern with the Biotherapeutics department for 9 months before joining the SIS Cloud Team in the capacity of a Business Analyst for the last 5 months. Her experiences include cellular/molecular biology, protein expression and characterization, molecular modeling, bioinformatics, and precision medicine molecular modeling. As a Business Analyst, she has worked on cloud application testing, documentation, advising on user problems and proposing solutions to address these scientific challenges.

Jeff Johnson, Principal Scientist, Biotherapeutics, Celgene Corporation, San Diego, CA, USA
Jeff has been employed at the following institutions: Fred Hutchinson Cancer Research Center, Corixa, Seattle Genetics, Ikaria, Allozyne, Bristol-Myers Squibb, and Celgene. Varied experience includes molecular/cellular biology, protein expression and expression engineering, ADC platform development, single cell cloning platform implementation of manufacturing cell lines, and early R&D biologics project coordination and management.

Yu Liu, Associate Director, Cloud Solution Partner, Celgene Corporation, San Diego, CA, USA
David spent the last 10 years in the pharmaceutical and biotech industry building and architecting data integration and analysis platforms for biotherapeutics organizations. His projects range from cloud native high-throughput data manipulations to statistical machine learning algorithms, helping scientists better summarize, comprehend, and make rational decisions. For the last several years, his development centralized around Genedata for large pharmaceutical companies facilitating rapid data capture and generating novel analytical insights. David has extensive experience in antibody discovery platforms, biologics data analysis, cloud distributed computing, RepSeq pipelines, and machine learning data science.

Jon Lloyd, Sr. Research Associate, Biotherapeutics, Celgene Corporation, San Diego, CA, USA
Jonathan received his B.S. (2015) and M.S. (2016) in Bioengineering from UC, Riverside. Throughout his time there he was involved in various research groups focused in Analytical Chemistry and Bioengineering. Most of his efforts were focused on modeling and experimental implementation of various protein-ligand interactions in vitro. Many of these ligands ranged from proteins and oligonucleotide aptamers to synthetic organic receptors. At Celgene he works on the screening and SPR characterization of therapeutic antibodies in the research and early development phase.

Andrew Lynch, Scientific Consultant, Genedata, Boston, MA, USA
Andrew Lynch is a scientific consultant at Genedata, working with customers to address data management needs for antibody, RNA, and other large molecule therapeutics. Prior to joining Genedata, he worked as an analyst for Boston University’s Office of Technology Development specializing in life sciences technologies and new ventures. Andrew earned his PhD in Biochemistry from Boston University, where his research focused on fragment-based drug design for protein-protein interactions and membrane protein crystallization.

Ruo Steensma, IT Director, Business Technology Leader, Research Lab Systems, Janssen Research and Development, La Jolla, CA, USA
Ruo Steensma received her Ph.D. degree in chemistry from The Scripps Research Institute and has been in pharmaceutical industry for 20 years. She is currently a Director and Business Technology Leader at Janssen Pharmaceuticals, a division of Johnson and Johnson. She has led numerous efforts in deploying data management solutions for both small and large molecule research and development. Ruo also has firsthand and in-depth knowledge of pharmaceutical R&D process and advanced molecules to clinic. Combining her expertise in both information technology and pharmaceutical discovery process, she is an expert in identifying pain points for scientists and selecting the right solutions for specific needs.

Bhavya Vivek, Associate Scientist, Biotherapeutic, Celgene Corporation, San Diego, CA, USA
Bhavya Vivek is an Associate Scientist in the Biotherapeutics Department at Celgene and her primary role is protein expression, early cell-line development and exploration/implementation of automation solutions for expression workflows. She is also tasked with helping other scientists learn various Genedata Biologics workflows that are pertinent to their needs. She was previously employed at Takeda Pharmaceuticals in a similar role, with a deeper focus on production cell-line development. She received her M.S in Cell and Molecular Biology at San Diego State University where she studied the role of immune responses in tumor aggressiveness and racial disparities observed in Colorectal Cancer.